Effect of Dietary Salt on Regulation of TGF-β in the Kidney

Seminars in Nephrology

Volumn 32, Issue 3, 2012, Pages 269-276

  Hovater, Michael B ^a   Sanders, Paul W ^a,b,c  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Fibrosis; Kidney; Salt; Sodium chloride; Transforming growth factor

Indexed keywords

FOCAL ADHESION KINASE 2; LARGE CONDUCTANCE CALCIUM ACTIVATED POTASSIUM CHANNEL; MITOGEN ACTIVATED PROTEIN KINASE; NITRIC OXIDE; PROTEIN KINASE B; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

APOPTOSIS; ARTICLE; ENDOTHELIUM CELL; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; GLOMERULUS; HUMAN; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY FIBROSIS; KIDNEY INJURY; NEPHRON; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SALT INTAKE; SIGNAL TRANSDUCTION; VASCULARIZATION;

ANIMALS; ENDOTHELIAL CELLS; EPITHELIAL-MESENCHYMAL TRANSITION; FIBROSIS; FOCAL ADHESION KINASE 2; HUMANS; KIDNEY; KIDNEY FAILURE, CHRONIC; LARGE-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS; MICE; MITOGEN-ACTIVATED PROTEIN KINASES; NITRIC OXIDE; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RENAL INSUFFICIENCY, CHRONIC; SIGNAL TRANSDUCTION; SMAD PROTEINS; SODIUM CHLORIDE, DIETARY; SRC-FAMILY KINASES; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84864153891     PISSN: 02709295     EISSN: 15584488     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2012.04.006     Document Type: Article

References (95)

1. Allen F.M. Arterial hypertension. JAMA 1920, 74:652-655.
2. Kempner W. Treatment of kidney disease and hypertensive vascular disease with the rice diet. N C Med J 1944, 5:125-133.
3. Meneely G.R., Tucker R.G., Darby W.J. Chronic sodium chloride toxicity in the albino rat. I. Growth on a purified diet containing various levels of sodium chloride. J Nutr 1952, 48:489-498.
4. Meneely G.R., Tucker R.G., Darby W.J., Auerbach S.H. Chronic sodium chloride toxicity in the albino rat. II. Occurrence of hypertension and of a syndrome of edema and renal failure. J Exp Med 1953, 98:71-80.
5. Tucker R.G., Ball C.O., Darby W.J., Early W.R., Kory R.C., Youmans J.B., et al. Chronic sodium chloride toxicity in the albino rat. III. Maturity characteristics, survivorship, and organ weights. J Gerontol 1957, 12:182-189.
6. Meneely G.R., Ball C.O. Experimental epidemiology of chronic sodium chloride toxicity and the protective effect of potassium chloride. Am J Med 1958, 25:713-725.
7. Ying W.Z., Sanders P.W. Dietary salt modulates renal production of transforming growth factor-β in rats. Am J Physiol 1998, 274:F635-F641.
8. Yu H.C.M., Burrell L.M., Black M.J., Wu L.L., Dilley R.J., Cooper M.E., et al. Salt induces myocardial and renal fibrosis in normotensive and hypertensive rats. Circulation 1998, 98:2621-2628.
9. Roberts A.B., Lamb L.C., Newton D.L., Sporn M.B., De Larco J.E., Todaro G.J. Transforming growth factors: isolation of polypeptides from virally and chemically transformed cells by acid/ethanol extraction. Proc Natl Acad Sci U S A 1980, 77:3494-3498.
10. Ikeda T., Lioubin M.N., Marquardt H. Human transforming growth factor type beta 2: production by a prostatic adenocarcinoma cell line, purification, and initial characterization. Biochemistry 1987, 26:2406-2410.
11. Derynck R., Lindquist P.B., Lee A., Wen D., Tamm J., Graycar J.L., et al. A new type of transforming growth factor-beta, TGF-beta 3. EMBO J 1988, 7:3737-3743.
12. Roberts A.B., Sporn M.B., Assoian R.K., Smith J.M., Roche N.S., Wakefield L.M., et al. Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci U S A 1986, 83:4167-4171.
13. Rosenbloom J., Castro S.V., Jimenez S.A. Narrative review: fibrotic diseases: cellular and molecular mechanisms and novel therapies. Ann Intern Med 2010, 152:159-166.
14. Blobe G.C., Schiemann W.P., Lodish H.F. Role of transforming growth factor beta in human disease. N Engl J Med 2000, 342:1350-1358.
15. Prud'homme G.J. Pathobiology of transforming growth factor beta in cancer, fibrosis and immunologic disease, and therapeutic considerations. Lab Invest 2007, 87:1077-1091.
16. Proetzel G., Pawlowski S.A., Wiles M.V., Yin M., Boivin G.P., Howles P.N., et al. Transforming growth factor-beta 3 is required for secondary palate fusion. Nat Genet 1995, 11:409-414.
17. Goumans M.J., Liu Z., ten Dijke P. TGF-beta signaling in vascular biology and dysfunction. Cell Res 2009, 19:116-127.
18. Miyazono K., Hellman U., Wernstedt C., Heldin C.H. Latent high molecular weight complex of transforming growth factor beta 1. Purification from human platelets and structural characterization. J Biol Chem 1988, 263:6407-6415.
19. Wakefield L.M., Smith D.M., Flanders K.C., Sporn M.B. Latent transforming growth factor-beta from human platelets. A high molecular weight complex containing precursor sequences. J Biol Chem 1988, 263:7646-7654.
20. Wakefield L.M., Smith D.M., Broz S., Jackson M., Levinson A.D., Sporn M.B. Recombinant TGF-beta 1 is synthesized as a two-component latent complex that shares some structural features with the native platelet latent TGF-beta 1 complex. Growth Factors 1989, 1:203-218.
21. Miyazono K., Heldin C.H. Latent forms of TGF-beta: molecular structure and mechanisms of activation. Ciba Found Symp 1991, 157:81-92.
22. Frolik C.A., Wakefield L.M., Smith D.M., Sporn M.B. Characterization of a membrane receptor for transforming growth factor-beta in normal rat kidney fibroblasts. J Biol Chem 1984, 259:10995-11000.
23. Wrana J.L., Attisano L., Wieser R., Ventura F., Massagué J. Mechanism of activation of the TGF-beta receptor. Nature 1994, 370:341-347.
24. Massagué J., Attisano L., Wrana J.L. The TGF-beta family and its composite receptors. Trends Cell Biol 1994, 4:172-178.
25. Brown K.A., Pietenpol J.A., Moses H.L. A tale of two proteins: differential roles and regulation of Smad2 and Smad3 in TGF-beta signaling. J Cell Biochem 2007, 101:9-33.
26. García-Sánchez O., López-Hernández F.J., López-Novoa J.M. An integrative view on the role of TGF-beta in the progressive tubular deletion associated with chronic kidney disease. Kidney Int 2010, 77:950-955.
27. Böttinger E.P., Bitzer M. TGF-beta signaling in renal disease. J Am Soc Nephrol 2002, 13:2600-2610.
28. Hills C.E., Squires P.E. TGF-beta1-induced epithelial-to-mesenchymal transition and therapeutic intervention in diabetic nephropathy. Am J Nephrol 2010, 31:68-74.
29. Strutz F., Müller G.A., Neilson E.G. Transdifferentiation: a new angle on renal fibrosis. Exp Nephrol 1996, 4:267-270.
30. Masszi A., Di Ciano C., Sirokmány G., Arthur W.T., Rotstein O.D., Wang J., et al. Central role for Rho in TGF-beta1-induced alpha-smooth muscle actin expression during epithelial-mesenchymal transition. Am J Physiol Renal Physiol 2003, 284:F911-F924.
31. Yang J., Liu Y. Dissection of key events in tubular epithelial to myofibroblast transition and its implications in renal interstitial fibrosis. Am J Pathol 2001, 159:1465-1475.
32. Iwano M., Plieth D., Danoff T.M., Xue C., Okada H., Neilson E.G. Evidence that fibroblasts derive from epithelium during tissue fibrosis. J Clin Invest 2002, 110:341-350.
33. Oba S., Kumano S., Suzuki E., Nishimatsu H., Takahashi M., Takamori H., et al. miR-200b precursor can ameliorate renal tubulointerstitial fibrosis. PLoS One 2010, 5:e13614.
34. Kang Y.S., Li Y., Dai C., Kiss L.P., Wu C., Liu Y. Inhibition of integrin-linked kinase blocks podocyte epithelial-mesenchymal transition and ameliorates proteinuria. Kidney Int 2010, 78:363-373.
35. Kaneyama T., Kobayashi S., Aoyagi D., Ehara T. Tranilast modulates fibrosis, epithelial-mesenchymal transition and peritubular capillary injury in unilateral ureteral obstruction rats. Pathology 2010, 42:564-573.
36. Zeisberg M., Hanai J., Sugimoto H., Mammoto T., Charytan D., Strutz F., et al. BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat Med 2003, 9:964-968.
37. Pletinck A., Consoli C., Van Landschoot M., Steppan S., Topley N., Passlick-Deetjen J., et al. Salt intake induces epithelial-to-mesenchymal transition of the peritoneal membrane in rats. Nephrol Dial Transplant 2010, 25:1688-1696.
38. Zavadil J., Bitzer M., Liang D., Yang Y.C., Massimi A., Kneitz S., et al. Genetic programs of epithelial cell plasticity directed by transforming growth factor-beta. Proc Natl Acad Sci U S A 2001, 98:6686-6691.
39. Ying W.Z., Sanders P.W. Dietary salt intake activates MAP kinases in the rat kidney. FASEB J 2002, 16:1683-1684.
40. Ying W.Z., Sanders P.W. The interrelationship between TGF-beta1 and nitric oxide is altered in salt-sensitive hypertension. Am J Physiol Renal Physiol 2003, 285:F902-F908.
41. Quaggin S.E., Kapus A. Scar wars: mapping the fate of epithelial-mesenchymal-myofibroblast transition. Kidney Int 2011 Mar 23, [cited 2011 Apr 30]. http://www.nature.com/ki/journal, 10.1038/ki.2011.77.
42. Humphreys B.D., Lin S.L., Kobayashi A., Hudson T.E., Nowlin B.T., Bonventre J.V., et al. Fate tracing reveals the pericyte and not epithelial origin of myofibroblasts in kidney fibrosis. Am J Pathol 2010, 176:85-97.
43. Koesters R., Kaissling B., Lehir M., Picard N., Theilig F., Gebhardt R., et al. Tubular overexpression of transforming growth factor-beta1 induces autophagy and fibrosis but not mesenchymal transition of renal epithelial cells. Am J Pathol 2010, 177:632-643.
44. Zeisberg M., Duffield J.S. Resolved: EMT produces fibroblasts in the kidney. J Am Soc Nephrol 2010, 21:1247-1253.
45. Yoo K.S., Nastiuk K.L., Krolewski J.J. Transforming growth factor beta1 induces apoptosis by suppressing FLICE-like inhibitory protein in DU145 prostate epithelial cells. Int J Cancer 2009, 124:834-842.
46. Yanagihara K., Tsumuraya M. Transforming growth factor beta 1 induces apoptotic cell death in cultured human gastric carcinoma cells. Cancer Res 1992, 52:4042-4045.
47. Sánchez A., Alvarez A.M., Benito M., Fabregat I. Apoptosis induced by transforming growth factor-beta in fetal hepatocyte primary cultures: involvement of reactive oxygen intermediates. J Biol Chem 1996, 271:7416-7422.
48. Rorke E.A., Jacobberger J.W. Transforming growth factor-beta 1 (TGF beta 1) enhances apoptosis in human papillomavirus type 16-immortalized human ectocervical epithelial cells. Exp Cell Res 1995, 216:65-72.
49. Miyajima A., Chen J., Lawrence C., Ledbetter S., Soslow R.A., Stern J., et al. Antibody to transforming growth factor-beta ameliorates tubular apoptosis in unilateral ureteral obstruction. Kidney Int 2000, 58:2301-2313.
50. Bhaskaran M., Reddy K., Radhakrishanan N., Franki N., Ding G., Singhal P.C. Angiotensin II induces apoptosis in renal proximal tubular cells. Am J Physiol Renal Physiol 2003, 284:F955-F965.
51. Dai C., Yang J., Liu Y. Transforming growth factor-beta1 potentiates renal tubular epithelial cell death by a mechanism independent of Smad signaling. J Biol Chem 2003, 278:12537-12545.
52. Ying W.Z., Sanders P.W. The interrelationship between TGF-beta1 and nitric oxide is altered in salt-sensitive hypertension. Am J Physiol Renal Physiol 2003, 285:F902-F908.
53. Border W.A., Okuda S., Languino L.R., Ruoslahti E. Transforming growth factor-beta regulates production of proteoglycans by mesangial cells. Kidney Int 1990, 37:689-695.
54. Border W.A., Okuda S., Languino L.R., Sporn M.B., Ruoslahti E. Suppression of experimental glomerulonephritis by antiserum against transforming growth factor beta 1. Nature 1990, 346:371-374.
55. Ying W.Z., Sanders P.W. Dietary salt intake activates MAP kinases in the rat kidney. FASEB J 2002, 16:1683-1684.
56. Sano Y., Harada J., Tashiro S., Gotoh-Mandeville R., Maekawa T., Ishii S. ATF-2 is a common nuclear target of Smad and TAK1 pathways in transforming growth factor-beta signaling. J Biol Chem 1999, 274:8949-8957.
57. Watanabe H., de Caestecker M.P., Yamada Y. Transcriptional cross-talk between Smad, ERK1/2, and p38 mitogen-activated protein kinase pathways regulates transforming growth factor-beta-induced aggrecan gene expression in chondrogenic ATDC5 cells. J Biol Chem 2001, 276:14466-14473.
58. Sorrentino A., Thakur N., Grimsby S., Marcusson A., von Bulow V., Schuster N., et al. The type I TGF-beta receptor engages TRAF6 to activate TAK1 in a receptor kinase-independent manner. Nat Cell Biol 2008, 10:1199-1207.
59. Sanders P.W. Salt intake, endothelial cell signaling, and progression of kidney disease. Hypertension 2004, 43:142-146.
60. Avraham H., Park S.Y., Schinkmann K., Avraham S. RAFTK/Pyk2-mediated cellular signalling. Cell Signal 2000, 12:123-133.
61. Lev S., Moreno H., Martinez R., Canoll P., Peles E., Musacchio J.M., et al. Protein tyrosine kinase PYK2 involved in Ca(2+)-induced regulation of ion channel and MAP kinase functions. Nature 1995, 376:737-745.
62. Pandey P., Avraham S., Kumar S., Nakazawa A., Place A., Ghanem L., et al. Activation of p38 mitogen-activated protein kinase by PYK2/related adhesion focal tyrosine kinase-dependent mechanism. J Biol Chem 1999, 274:10140-10144.
63. Ying W.Z., Aaron K., Sanders P.W. Mechanism of dietary salt-mediated increase in intravascular production of TGF-beta1. Am J Physiol Renal Physiol 2008, 295:F406-F414.
64. McMullen M., Keller R., Sussman M., Pumiglia K. Vascular endothelial growth factor-mediated activation of p38 is dependent upon Src and RAFTK/Pyk2. Oncogene 2004, 23:1275-1282.
65. Chen P.Y., Sanders P.W. L-arginine abrogates salt-sensitive hypertension in Dahl/Rapp rats. J Clin Invest 1991, 88:1559-1567.
66. Chen P.Y., Sanders P.W. Role of nitric oxide synthesis in salt-sensitive hypertension in Dahl/Rapp rats. Hypertension 1993, 22:812-818.
67. Shultz P.J., Tolins J.P. Adaptation to increased dietary salt intake in the rat. Role of endogenous nitric oxide. J Clin Invest 1993, 91:642-650.
68. Bech J.N., Nielsen C.B., Ivarsen P., Jensen K.T., Pedersen E.B. Dietary sodium affects systemic and renal hemodynamic response to NO inhibition in healthy humans. Am J Physiol 1998, 274:F914-F923.
69. Inoue N., Venema R.C., Sayegh H.S., Ohara Y., Murphy T.J., Harrison D.G. Molecular regulation of the bovine endothelial cell nitric oxide synthase by transforming growth factor-beta 1. Arterioscler Thromb Vasc Biol 1995, 15:1255-1261.
70. Ying W.Z., Aaron K., Sanders P.W. Dietary salt activates an endothelial proline-rich tyrosine kinase 2/c-Src/phosphatidylinositol 3-kinase complex to promote endothelial nitric oxide synthase phosphorylation. Hypertension 2008, 52:1134-1141.
71. Kolluru G.K., Siamwala J.H., Chatterjee S. eNOS phosphorylation in health and disease. Biochimie 2010, 92:1186-1198.
72. Fulton D., Gratton J.P., McCabe T.J., Fontana J., Fujio Y., Walsh K., et al. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature 1999, 399:597-601.
73. Fulton D., Gratton J.P., Sessa W.C. Post-translational control of endothelial nitric oxide synthase: why isn't calcium/calmodulin enough?. J Pharmacol Exp Ther 2001, 299:818-824.
74. Lane P., Gross S.S. Disabling a C-terminal autoinhibitory control element in endothelial nitric-oxide synthase by phosphorylation provides a molecular explanation for activation of vascular NO synthesis by diverse physiological stimuli. J Biol Chem 2002, 277:19087-19094.
75. Matsui A., Okigaki M., Amano K., Adachi Y., Jin D., Takai S., et al. Central role of calcium-dependent tyrosine kinase PYK2 in endothelial nitric oxide synthase-mediated angiogenic response and vascular function. Circulation 2007, 116:1041-1051.
76. Sanders P.W. Vascular consequences of dietary salt intake. Am J Physiol Renal Physiol 2009, 297:F237-F243.
77. Davis J.M., Häberle D.A., Kawata T. The control of glomerular filtration rate and renal blood flow in chronically volume-expanded rats. J Physiol 1988, 402:473-495.
78. Ying W.Z., Sanders P.W. Dietary salt enhances glomerular endothelial nitric oxide synthase through TGF-beta1. Am J Physiol 1998, 275:F18-F24.
79. Ohno M., Cooke J.P., Dzau V.J., Gibbons G.H. Fluid shear stress induces endothelial transforming growth factor beta-1 transcription and production. Modulation by potassium channel blockade. J Clin Invest 1995, 95:1363-1369.
80. Ying W.Z., Aaron K., Wang P.X., Sanders P.W. Potassium inhibits dietary salt-induced transforming growth factor-beta production. Hypertension 2009, 54:1159-1163.
81. Collins A.J., Foley R.N., Herzog C., Chavers B., Gilbertson D., Ishani A., et al. US Renal Data System 2010 annual data report. Am J Kidney Dis 2011, 57(Suppl 1):e1-e526. A8.
82. Gunn J.P., Kuklina E.V., Keenan N.L., Labarthe D.R. Sodium intake among adults-United States, 2005-2006. MMWR Morb Mortal Wkly Rep 2010, 59:746-749.
83. Stolarz-Skrzypek K., Kuznetsova T., Thijs L., Tikhonoff V., Seidlerová J., Richart T., et al. Fatal and nonfatal outcomes, incidence of hypertension, and blood pressure changes in relation to urinary sodium excretion. JAMA 2011, 305:1777-1785.
84. du Cailar G., Ribstein J., Mimran A. Dietary sodium and target organ damage in essential hypertension. Am J Hypertens 2002, 15:222-229.
85. Verhave J.C., Hillege H.L., Burgerhof J.G., Janssen W.M., Gansevoort R.T., Navis G.J., et al. Sodium intake affects urinary albumin excretion especially in overweight subjects. J Intern Med 2004, 256:324-330.
86. Vedovato M., Lepore G., Coracina A., Dodesini A.R., Jori E., Tiengo A., et al. Effect of sodium intake on blood pressure and albuminuria in type 2 diabetic patients: the role of insulin resistance. Diabetologia 2004, 47:300-303.
87. He F.J., Marciniak M., Visagie E., Markandu N.D., Anand V., Dalton R.N., et al. Effect of modest salt reduction on blood pressure, urinary albumin, and pulse wave velocity in white, black, and Asian mild hypertensives. Hypertension 2009, 54:482-488.
88. Swift P.A., Markandu N.D., Sagnella G.A., He F.J., MacGregor G.A. Modest salt reduction reduces blood pressure and urine protein excretion in black hypertensives: a randomized control trial. Hypertension 2005, 46:308-312.
89. Weinberger M.H., Fineberg N.S., Fineberg S.E., Weinberger M. Salt sensitivity, pulse pressure, and death in normal and hypertensive humans. Hypertension 2001, 37:429-432.
90. Cook N.R., Cutler J.A., Obarzanek E., Buring J.E., Rexrode K.M., Kumanyika S.K., et al. Long term effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the trials of hypertension prevention (TOHP). BMJ 2007, 334:885-888.
91. Mohan S., Campbell N.R., Willis K. Effective population-wide public health interventions to promote sodium reduction. CMAJ 2009, 181:605-609.
92. He F.J., MacGregor G.A. A comprehensive review on salt and health and current experience of worldwide salt reduction programmes. J Hum Hypertens 2009, 23:363-384.
93. Webster J.L., Dunford E.K., Hawkes C., Neal B.C. Salt reduction initiatives around the world. J Hypertens 2011, 29:1043-1050.
94. Asaria P., Chisholm D., Mathers C., Ezzati M., Beaglehole R. Chronic disease prevention: health effects and financial costs of strategies to reduce salt intake and control tobacco use. Lancet 2007, 370:2044-2053.
95. Murray C.J., Lauer J.A., Hutubessy R.C., Niessen L., Tomijima N., Rodgers A., et al. Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk. Lancet 2003, 361:717-725.